Evaluation of Safety, Tolerability, PK & PD of Intravenous VX15/2503 in Patients With Advanced Solid Tumors
Study Details
Study Description
Brief Summary
The purpose of this study is to evaluate the safety and tolerability of IV administration of VX15/2503 in patients with advanced solid tumors. The escalation part of the study will determine the maximum tolerated dose (MTD).
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 1 |
Detailed Description
VX15/2503-01 is a dose-escalation, open label study to evaluate the safety and tolerability of IV administered VX15/2503 in patients with advanced solid tumors. This will be accomplished by using a dose escalation procedure starting at low doses of VX15/2503 and will continue based on predefined parameters until the maximum tolerated dose is identified.
The study drug, VX15/2503, is a monoclonal antibody that binds to the semaphorin 4D (SEMA4D; CD100) antigen. Semaphorins have been shown to play an important role in certain physiological processes such as vascular growth, tumor progression and immune cell regulation. Experimental evidence suggests that SEMA4D has two mechanisms of action that result in angiogenesis and tumor proliferation and invasion. Antibody neutralization of SEMA4D thus may represent a new therapeutic strategy for cancer treatment.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: VX15/2503 VX15/2503 monoclonal antibody at a concentration of 0.3 mg/kg - 20 mg/kg to be administered intravenously on a weekly dosing cycle. |
Drug: VX15/2503
Dose escalation will begin at low doses and will gradually increase in each future cohort. The current trial design provides for 7 study cohorts with a 20 mg/kg expansion phase.
|
Outcome Measures
Primary Outcome Measures
- Safety/tolerability as measured by number of patients with adverse events [Up to 18 months]
Subject incidence of treatment-emergent adverse events
- Maximum tolerated dose as measured by frequency of dose limiting toxicities [Four (4) weeks after first dose]
Secondary Outcome Measures
- Peak plasma concentration (Cmax) of VX15/2503 [Four (4) hours after start of infusion]
- Area under the plasma concentration versus time curve (AUC) of VX15/2503 [Up to seven (7) days after first dose]
- Half-life of VX15/2503 [Up to 14 days after first dose]
Other Outcome Measures
- SEMA4D T cell percent saturation of VX15/2503 [Up to 18 months]
- Number of patients who develop anti-drug antibody [Up to 18 months]
- Overall response rate (ORR) using RECIST 1.1 [Up to 18 months]
- Progression-free survival (PFS) using RECIST 1.1 [Up to 18 months]
Eligibility Criteria
Criteria
Main Inclusion Criteria:
-
Patients 18 yrs or older with confirmed histological or cytological advanced solid tumors, relapsed or refractory to standard treatment for which no curative therapy is available; patients must demonstrate progressive disease prior to entry
-
Has measurable disease as defined by RECIST1.1
-
Life expectancy of at least 3 months (per investigator assessment)
-
ECOG performance status of 0-2
-
Adequate bone marrow, renal and liver function
-
Recovered from any significant prior toxicity of previous anti-neoplastic therapy
-
For patients of reproductive potential, is willing to use a medically acceptable form of contraception throughout the study period and for at least 4 weeks after the last dose of VX15/2503
-
Expansion cohort - patients in this cohort must have one of the following characteristics:
-
A diagnosis of a pancreatic neuroendocrine tumor OR
-
A diagnosis of a soft tissue sarcoma OR
-
A diagnosis of a bone metastasis OR
-
A diagnosis of advanced solid tumor AND a T cell count of at least 1500 cells/uL OR a B cell count of at least 250 cells/uL at screening
Main Exclusion Criteria:
-
Treatment with anti-neoplastic agents (chemotherapy, immunotherapy, radiotherapy or endocrine therapy) within 3 weeks prior to start of study treatment
-
Treatment with an investigational agent within 4 weeks prior to start of study treatment
-
Is on concurrent anti-neoplastic therapy with the exception of continuing luteinizing hormone-releasing hormone agonist/antagonist therapy for patients with castrate-resistant prostate cancer
-
Treatment with oral or parenteral corticosteroids in excess of 10mg/day of prednisolone or equivalent for more than 5 days within 4 weeks prior to start of study treatment or a requirement for systemic immunosuppressive therapy for any reason
-
Untreated brain Mets or CNS tumor involvement
-
Any other intercurrent illness or condition which could impact patient compliance or ability to complete the study
-
Sensitivity to VX15/2503 or the ingredients or excipients of VX15/2503
-
Pregnant or breast-feeding women (women of child-bearing potential must have negative serum pregnancy test within 3 days prior to receiving the first dose of VX15/2503)
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Virginia G. Piper Cancer Center at Scottsdale Healthcare | Scottsdale | Arizona | United States | 85258 |
| 2 | South Texas Accelerated Research Therapeutics, LLC | San Antonio | Texas | United States | 78229 |
Sponsors and Collaborators
- Vaccinex Inc.
- PPD
Investigators
- Principal Investigator: Amita Patnaik, MD, South Texas Accelerated Research Therapeutics, LLC
- Principal Investigator: Ramesh K Ramanathan, MD, TGen Clinical Research Service at Scottsdale Healthcare
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- VX15/2503-01 v.9